Newron Pharmaceuticals to Present at SIRS 2026

Newron Pharmaceuticals S.p.A. announced its participation in the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) in Florence, Italy. The event will be held from March 25-29, 2026, at Firenze Fiera. Newron plans to contribute through a workshop and the presentation of three posters, focusing on the modulation of glutamate in treatment-resistant schizophrenia (TRS).

The workshop, scheduled for March 25, will discuss the modulation of glutamate in TRS patients and share results from trials involving Evenamide. Subsequently, Newron will present novel findings further supporting the potential of Evenamide in treating TRS through animal models and the Phase III ENIGMA-TRS program.

Evenamide, a novel chemical entity, uniquely targets voltage-gated sodium channels, offering hope for those with inadequate responses to current antipsychotics. The ENIGMA-TRS program aims to evaluate its efficacy and safety further.